Drugs / bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)
bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02212106 | Sep → Dec 2014 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bioCSL Trivalent Influenza Virus Vaccine (CSL TIV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02212106 ↗ |
| Modality | Vaccine | “Trivalent Influenza Virus Vaccine” NCT02212106 ↗ |
| Route | Intramuscular | “The vaccine will be administered by intramuscular injection.” NCT02212106 ↗ |